Endocrinology | Home | MIMS Malaysia

Endocrinology

Bedtime glucose, next-day fasting glucose may be indicators of hypoglycaemia in T1D

Yesterday

Low levels of glucose at bedtime of the previous day and fasting glucose appear to be reasonably predictive of nocturnal asymptomatic, serious, clinically important hypoglycaemia in type 1 diabetes (T1D) patients taking insulin degludec (IDeg), a new study has found.

Bariatric revision will do the job for patients with persistent obesity-related conditions

Jairia Dela Cruz, Yesterday

Patients who have undergone weight-loss surgery may sometimes have to return for revision, which helps improve outcomes associated with obesity, such as diabetes and hypertension, according to a meta-analysis.

Generic measures up to branded exenatide for uncontrolled T2DM

2 days ago

There appear to be minimal differences between generic and branded exenatide when used as an add-on therapy in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues, a study has found.

Sleep-disordered breathing may be a risk factor for glucose elevations in GDM

4 days ago

Among women with gestational diabetes mellitus (GDM), increased severity of sleep-disordered breathing is associated with poor glycaemic control during the night and early morning, a study has found.

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020

In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

Early Treatment Intensification in T2DM, The Time is Now

29 Jun 2020

At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.

HK in CKD: Do diet, HD frequency matter?

Elvira Manzano, 28 Jun 2020

Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.

Empagliflozin’s clinical endorsement: Revolutionising guidelines across specialties

08 Jun 2020

In this third issue we take a look at how empagliflozin made a bold impact on clinical guidelines across multiple specialties. We will explore how existing treatment recommendations were altered, and summarise the current guidelines and future perspectives of empagliflozin’s use.

Empagliflozin’s cardiovascular benefits lead the change in T2D treatment paradigm

11 May 2020

This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.

Ticagrelor benefits in TWILIGHT hold up in diabetes

Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

One-quarter of calorie intake in children derived from empty calories

Roshini Claire Anthony, 28 Jul 2020

About one-quarter of the calories consumed by children and adolescents may be acquired from empty calories, according to a US-based study presented at Nutrition 2020 Live Online.

EMPRISE reinforces CV benefits of empagliflozin

Elvira Manzano, 28 Jul 2020

The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE⁺ study presented at ADA 2020.

Does spacing pregnancies help women with gestational diabetes?

Elvira Manzano, 28 Jul 2020

Women with a history of gestational diabetes were 50 percent more likely to have a short interval between pregnancies compared to women without the condition, suggests a new study.

Dapagliflozin may prevent new-onset T2D

Roshini Claire Anthony, 23 Jul 2020

Dapagliflozin reduced the incidence of new-onset type 2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF), according to a prespecified exploratory analysis of the DAPA-HF* trial.

Insulin detemir use not tied to adverse pregnancy outcomes

Elaine Soliven, 18 Jul 2020

The use of insulin detemir among women with pre-existing diabetes was not associated with an increased risk of negative pregnancy outcomes, such as major congenital malformations and perinatal or neonatal deaths, compared with other basal insulins, according to the EVOLVE* study.

Icosapent ethyl may REDUCE CV risk in diabetes

Roshini Claire Anthony, 17 Jul 2020

Icosapent ethyl may reduce the risk of cardiovascular (CV) events in patients with diabetes mellitus (DM) taking statins, according to findings of REDUCE-IT DIABETES presented at ADA 2020.